|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||N/A - N/A|
|52-week range||undefined - undefined|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
On December 28, Becton, Dickinson and Company (BDX), or BD, received clearance for its Bard (BCR) acquisition form MOFCOM (Ministry of Commerce of the People's Republic of China), but the approval is contingent ...
Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.
Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.
The Murray Hill, New Jersey-based company said it had net income of $1.25 per share. Earnings, adjusted for one-time gains and costs, came to $3.02 per share. The results beat Wall Street expectations. ...
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.